cs 1

CS1 is a potent DNA Topo II α inhibitor that exhibits broad-spectrum antitumor effects in vitro, low toxicity in vivo, and potential anti-multidrug resistance capabilities. CS1 induces DNA damage, G2 M phase cell cycle arrest, and apoptosis [1].

CS1 peptide is present within type III homology connecting segment (IIICS) as well as C-274 (cell-binding domain). Fibronectin CS1 Peptide lacks the Arg-Gly-Asp-containing domain, actively inhibits tumor metastases in spontaneous and experimental metastas

Delcasertib acetate is a selective δ protein kinase C (δPKC) inhibitor for the study of acute myocardial infarction and pain.

he connecting segment 1 (CS-1) is a cell attachment domain located in the type III homology connecting segment (IIICS) of fibronectin. CS1 peptide of fibronectin, which lacks the Arg-Gly-Asp-containing domain, actively inhibits tumor metastases in spontan

BMS-536924 (BMS 536924) is an ATP-competitive IGF-1R IR inhibitor with IC50 of 100 nM 73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1 2.

Loxoprofen sodium (CS-600) is an effective and oral sodium inhibitor of COX-1 and COX-2 with IC50 of 6.5 and 13.5 μM, respectively. Loxoprofen sodium works by reducing the synthesis of prostaglandins from arachidonic acid. Loxoprofen sodium has anti-inflammatory and antitumor activity and can be used to treat atherosclerosis.

CS-0047390, also known as tert-Butyl-DCL, PSMA inhibitor, is a radiopaque peptide reagent.

CS 2100 (1-[[4-Ethyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]-3-azetidinecarboxylic acid) is an S1P1 agonist.

CS-0777 is a potent, selective, and orally active S1P1 agonist (sphingosine 1-phosphate receptor modulator).

Octanoyl coenzyme A triammonium, a medium-chain acyl coenzyme A, can inhibit citrate synthase (CS) and glutamate dehydrogenase (GDH) with IC50 values of 0.4-1.6 mM [1].

EGFR-IN-70 is a potent EGFR inhibitor with IC 50 values of 23.6 and 307.5 nM for EGFR LR/TM/CS and EGFR WT , respectively. EGFR-IN-70 has anti-proliferative activity and suppresses phosphorylation of the EGFR . EGFR-IN-70 can be used for cancer research .

Tigatuzumab (CS-1008), a humanized IgG1 monoclonal antibody, specifically targets death receptor 5 (DR5), inducing apoptosis in cancer cells and inhibiting tumor growth in vivo. It holds potential for cancer research applications [1].

Adrenocorticotropic Hormone (ACTH) (1-39) human (TFA), a member of the melanocortin family, is a melanocortin receptor agonist that stimulates corticosteroid production by the adrenals; melanocortin receptors are also located in the central nervous system (CNS) and on immune cells.

Pactimibe sulfate (CS-505) is a dual ACAT1 2 inhibitor, acting on ACAT1 (IC50: 4.9 μM) and ACAT2 (IC50: 3.0 μM). It inhibits oleoyl-CoA non-competitively (Ki: 5.6 μM) and significantly inhibits cholesterol ester formation (IC50: 6.7 μM). Pactimibe sulfate reduces plasma cholesterol activity and has anti-atherogenic potential.

Chst15-IN-1 is a powerful, reversible, covalent inhibitor of the Chst15 enzyme. It effectively suppresses the sulfation levels of chondroitin sulfate-E (CS-E) and other closely related sulfotransferases responsible for glycosaminoglycans (GAGs) synthesis. Acting as a selective sulfotransferase inhibitor, Chst15-IN-1 can attenuate the inhibitory actions of chondroitin sulfate proteoglycans (CSPGs), making it a promising candidate for enhancing neuronal repair.

Linafexor (CS-0159) acts as an agonist for the farnesoid X receptor (FXR) [1].

Chiauranib is a multi-target inhibitor against tumor angiogenesis and exhibits potent anticancer effects. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF1R, with IC50 values ranging from 1-9 nM.